The Union government has decided to put on hold the rollout of a satellite-based highway toll collection system that could ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...

Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Sigma Planning Corp cut its holdings in Novartis AG (NYSE:NVS – Free Report) by 19.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,218 shares of the company’s stock after ...

Emasan AG, a subsidiary of the Sandoz Family Foundation, has initiated a public offering of approximately 26.5 million shares ...

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not ...

According to Benzinga Pro, Novartis's peer group average for short interest as a percentage of float is 4.09%, which means ...

ZURICH (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling ...

Qure's stock rises on Huntington's therapy progress and strong gene therapy pipeline. Learn about QURE stock's cost-cutting ...

Novartis AG’s Sandoz family sold a roughly 1.2% stake in the Swiss pharmaceutical group for 2.6 billion Swiss francs ($2.9 ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors in the Magnificent Seven stocks, take note. As Arnott wrote in an email: "Whoever coined the expression 'Magnificent Seven' for these companies presumably didn't see the movie, where four of ...